Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.69 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210950 | 0.84 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL210666 | 0.83 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL1064069 | 0.82 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC11HDAC8 | |
| SCHEMBL21642478 | 0.82 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL212368 | 0.82 | HDAC1 (0.61) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL8346533 | 0.81 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC8NCOR2 | |
| SCHEMBL23746024 | 0.81 | HDAC1 (0.90) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL8348463 | 0.80 | HDAC1 (0.83) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL13713672 | 0.80 | HDAC1 (0.74) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL210466 | 0.80 | HDAC1 (0.62) | HDAC1HDAC2HDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| CN-1997649-B | Inhibitors of histone deacetylase | METHYLGENE INC | 2010-08-11 | — | — | CN | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| CN-1997649-A | Inhibitors of histone deacetylase | METHYLGENE INC (CA) | 2007-07-11 | — | — | CN | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC2 10/4885HDAC3 4/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC2 12/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.